Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vioxx litigation update

Executive Summary

Merck is named as defendant in 2,300 Vioxx-related lawsuits, including 4,600 plaintiff groups alleging personal injuries following the use of the COX-2 inhibitor. The first trials are scheduled for May 23 in Alabama and May 31 in Texas. Merck has $675 mil. in reserve to cover the legal costs associated with the withdrawal of Vioxx in September 2004 (1"The Pink Sheet" Jan. 31, 2005, p. 7)...

You may also be interested in...

Merck Sets $604 Mil. Vioxx Legal Defense Reserve; PR Battles Continue

Merck will take a $604 mil. charge in the fourth quarter to establish a reserve for its defense of Vioxx litigation, an amount roughly equivalent to Singulair quarterly sales

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

Executive order calls for short-term and long-term study, broad consultation, coordination with allies.

Cosmetic And Personal Care Trademark Review 23 February, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts